SCHEDULE 13G/A 0000902664-23-005426 0001603466 XXXXXXXX LIVE 2 Common Stock, par value $0.001 per share 06/30/2025 0001703647 Korro Bio, Inc. 500946108 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141 Rule 13d-1(c) Point72 Asset Management, L.P. b DE 0.00 540074.00 0.00 540074.00 540074.00 N 5.8 PN Point72 Capital Advisors, Inc. b DE 0.00 540074.00 0.00 540074.00 540074.00 N 5.8 CO Point72 Biotech Private Investments, LLC b DE 0.00 276831.00 0.00 276831.00 276831.00 N 2.9 OO Differentiated Ventures Investments, LLC b DE 0.00 276831.00 0.00 276831.00 276831.00 N 2.9 OO 72 Investment Holdings, LLC b DE 0.00 276831.00 0.00 276831.00 276831.00 N 2.9 OO Steven A. Cohen b X1 0.00 816905.00 0.00 816905.00 816905.00 N 8.7 IN Korro Bio, Inc. 60 First Street, 2nd Floor, Suite 250, Cambridge, MA 02141. This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.001 per share ("Common Stock") of Korro Bio, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc."), the general partner of Point72 Asset Management, with respect to the shares of Common Stock held by Point72 Associates; (iii) Point72 Biotech Private Investments, LLC ("Point72 Biotech") with respect to the shares of Common Stock of which it is the holder; (iv) Differentiated Ventures Investments, LLC ("Differentiated Ventures"), the managing member of Point72 Biotech, with respect to the shares of Common Stock held by Point72 Biotech; (v) 72 Investment Holdings, LLC ("72 Investment Holdings"), the sole member of Differentiated Ventures, with respect to the shares of Common Stock held by Point72 Biotech, and (vi) Steven A. Cohen ("Mr. Cohen"), the sole member of 72 Investment Holdings and sole shareholder of Point72 Capital Advisors Inc., with respect to the shares of Common Stock beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings. The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902. Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings are Delaware limited liability companies. Mr. Cohen is a United States citizen. Y The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. Differentiated Ventures is the managing member of Point72 Biotech and may be deemed to share beneficial ownership over the shares of Common Stock held by Point72 Biotech. 72 Investment Holdings is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of Common Stock of which Differentiated Ventures may be deemed the beneficial owner. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities and Exchange Act of 1934, the beneficial owner of the Common Stock reported herein. 8.7% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. Y N See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding shares of Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Point72 Asset Management, L.P. /s/ Jason M. Colombo 08/14/2025 Point72 Capital Advisors, Inc. /s/ Jason M. Colombo 08/14/2025 Point72 Biotech Private Investments, LLC /s/ Vincent Tortorella 08/14/2025 Differentiated Ventures Investments, LLC /s/ Vincent Tortorella 08/14/2025 72 Investment Holdings, LLC /s/ Jason M. Colombo 08/14/2025 Steven A. Cohen /s/ Jason M. Colombo 08/14/2025